Breaking News: Actinium Pharmaceuticals (NYSE: ATNM) Makes Approx. 15% Early Move On Major Collaboration Announcement

*Sponsored Just Announced For Thursday March 20, 2025 Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is Our Next  Potential Breakout Idea. And Here’s Why… Analyst Coverage: Wall Street Analysts Have Issued Bullish Targets On Actinium Pharmaceuticals, Inc. (NYSE: ATNM), Highlighting Significant  Upside Potential. Recent Momentum: Actinium Pharmaceuticals, Inc. (NYSE: ATNM) Has Moved Approx. 26% Over 10 Sessions, Surpassing Key Moving Averages. Under The Radar: With A Market Cap Under $40M And A Float Below 32M Shares, Actinium Pharmaceuticals, Inc. (NYSE: ATNM) Fits A Structure  Tied To Higher Growth Potential. Intellectual Property Strength: With Hundreds Of Patents, Actinium Pharmaceuticals, Inc. (NYSE: ATNM) Has Secured A Strong Position In Targeted Radiotherapy. Keep Reading To See Why Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is Topping Our Watchlist This Morning… March 20, 2025 Dear Reader, Are you watching Actinium Pharmaceuticals, Inc. (NYSE: ATNM) yet? A high-profile partnership with Memorial Sloan Kettering Cancer Center (MSKCC) is set to push Actimab-A’s potential even further.  Actinium Pharmaceuticals, Inc. (NYSE: ATNM) just announced a research agreement to explore key combinations, including FLT3 and menin inhibitors, and test Actimab-A in patient-derived AML samples—even in cases where other treatments failed. At the same time, (ATNM) moved approximately 15% in the early session from $1.19 to $1.38, lighting up Multiple Bullish Signals on TradingView’s technical analysis tool while breaking past several key moving averages. With Phase 2/3 trials in motion and solid tumor studies underway with KEYTRUDA® and OPDIVO®, this breaking development could be a potential catalyst for Actinium Pharmaceuticals, Inc. (NYSE: ATNM).  If you missed my earlier coverage, keep reading to see why we’re so excited about  Actinium Pharmaceuticals, Inc. (NYSE: ATNM) right now. Every so often, a biotech company comes along with the potential to redefine how we fight cancer. This one isn’t just developing another therapy—it’s pioneering a breakthrough in targeted radiotherapy that could change the game.  And with Wall Street analysts setting targets several times higher than current levels, it’s clear this name is gaining serious attention. Take a look at why Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is topping our watchlist this morning. Over the course of 10 recent sessions, Actinium Pharmaceuticals, Inc. (NYSE: ATNM) has demonstrated bullish momentum, moving approximately 26% from around $1.02 on 3/4/2025, to $1.30 on 3/17/2025.  This has seen (ATNM) surpass several key moving averages according to Barchart including: -5-Day Moving Average: 1.22 -20-Day Moving Average: 1.1595 -50-Day Moving Average: 1.2044 With its 100-Day and 200-Day moving averages sitting at approximately 1.3424 and 2.8559, respectively, we’re keeping a very close eye on Actinium Pharmaceuticals, Inc. (NYSE: ATNM). But this is where it gets interesting… Analyst Ratings and Institutional Outlook Wall Street analysts have begun recognizing Actinium Pharmaceuticals, Inc. (NYSE: ATNM)’s potential, with multiple firms issuing strong targets: -Maxim Group: Analyst Jason McCarthy, Ph.D., has a $5 target that was published in a March 14, 2025 report, which suggests a 331% upside potential move from today’s $1.16 range . -HC Wainwright & Co.: Senior Healthcare Analyst Joseph Pantginis, Ph.D., reaffirmed a $4 target, as reported by Benzinga, which suggests 244% upside potential. -Stephens, Inc.: Analyst Sudan Loganathan, Ph.D., maintained an "Overweight" rating with a $5 target. Big names may dominate the headlines, but it’s the small and micro-cap companies flying under the radar that often make the biggest moves when the right catalyst hits. With a market cap under $40M and fewer than 32M shares in the float, Actinium Pharmaceuticals, Inc. (NYSE: ATNM) operates with the kind of tight structure that has historically fueled rapid growth when momentum builds.  Now, with analysts setting targets as high as $5, signaling potential upsides of 244% to 331%, this under-the-radar biotech may not stay unnoticed for long. Keep reading to see why Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is topping our watchlist this morning. About Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is a pioneer in targeted radiotherapy for oncology.  The company is advancing Actimab-A, a CD33-targeting therapeutic designed as a backbone therapy for acute myeloid leukemia (AML) and other myeloid malignancies.  Actimab-A leverages Actinium-225 (Ac-225), a mutation-agnostic alpha-emitter radioisotope, to deliver targeted radiotherapy directly to cancer cells. Key Developments: -Actimab-A has shown high rates of Complete Remission (CR) and measurable residual disease (MRD) negativity in relapsed and refractory AML (r/r AML) patients. -The candidate is advancing to a pivotal Phase 2/3 clinical trial, with potential implications for significantly improved patient outcomes. -Actinium is working with the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) to expand Actimab-A’s applications. Beyond AML, Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is also developing Actimab-A as a combination therapy for solid tumors, particularly in combination with PD-1 checkpoint inhibitors, such as: -KEYTRUDA® (Merck & Co.) -OPDIVO® (Bristol Myers Squibb) Breakthrough Potential in the Immuno-Oncology Market Actinium Pharmaceuticals, Inc. (NYSE: ATNM) recently announced a clinical trial program designed to evaluate the combination of Actimab-A with PD-1 inhibitors in treating solid tumors.  The rationale behind this program lies in tackling an emerging challenge in cancer treatment: -Myeloid-Derived Suppressor Cells (MDSCs), which accumulate in the tumor microenvironment, are known to reduce the effectiveness of PD-1 inhibitors like KEYTRUDA® and OPDIVO®. -Actimab-A selectively targets and depletes CD33-expressing MDSCs, a novel mechanism that could enhance the efficacy of PD-1 therapies. -If successful, this approach could open the door to a massive market in immuno-oncology with significant growth potential. Clinical Trials and Upcoming Catalysts Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is executing controlled, head-to-head clinical trials that will compare: -Actimab-A + KEYTRUDA® vs. KEYTRUDA® alone -Actimab-A + OPDIVO® vs. OPDIVO® alone Initial indications being targeted: -Head and Neck Squamous Cell Carcinoma (HNSCC) -Non-Small Cell Lung Cancer (NSCLC) These trials are designed to evaluate: -Overall Response Rate (ORR) -Progression-Free Survival (PFS) -Overall Survival (OS) -CD33+ MDSC depletion patterns and T-cell activity Actinium Pharmaceuticals, Inc. (NYSE: ATNM) expects to release initial proof-of-concept clinical data in late 2025, which could be a major catalyst for the company. The Competitive Advantage Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is working to establish itself as a key player in next-generation radiotherapy, backed by a strong intellectual property portfolio and a growing pipeline of targeted therapies.  The company holds 230 patents and patent applications, including critical protections related to the production of Actinium-225 (Ac-225) in a cyclotron—an essential component of its radiotherapy platform. Beyond its intellectual property, Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is advancing treatments for both hematologic and solid tumors.  Its pipeline includes Actimab-A, a targeted radiotherapy designed for acute myeloid leukemia (AML), as well as ongoing research into expanding its use in combination with PD-1 inhibitors for solid tumors. The company is also progressing with its Iomab-B program, which is being developed as an induction and conditioning agent for patients undergoing bone marrow transplants in relapsed or refractory AML.  Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is actively seeking a strategic partner for Iomab-B’s commercialization in the U.S. Management has expressed confidence in the potential of Actimab-A when combined with PD-1 checkpoint inhibitors, particularly given the prevalence of Myeloid-Derived Suppressor Cells (MDSCs) in solid tumors.  This patient population is estimated to be in the hundreds of thousands, representing a significant area of focus for future clinical advancements.  Preclinical data has shown encouraging results, reinforcing the belief that this novel combination approach could address an unmet need for patients whose cancers stop responding to PD-1 inhibitors. With a strong foundation in radiotherapy innovation, a growing clinical pipeline, and increasing attention from analysts, several key factors make Actinium Pharmaceuticals, Inc. (NYSE: ATNM) a name to watch right now. 7 Reasons Why Actinium Pharmaceuticals, Inc. (NYSE: ATNM) Is Topping Our Watchlist This Morning… 1. Analyst Coverage: Multiple Wall Street firms, including Maxim Group ($5), HC Wainwright & Co. ($4), and Stephens, Inc. ($5), have issued bullish targets, signaling what they see as a significant upside potential for Actinium Pharmaceuticals, Inc. (NYSE: ATNM) as attention on its developments grows. 2. Recent Momentum: Over a recent 10 sessions stretch, Actinium Pharmaceuticals, Inc. (NYSE: ATNM) has moved approximately 26%, surpassing several key moving averages along the way, which could suggest the potential for bullish momentum. 3. Under The Radar: With a market cap under $40M and fewer than 32M shares in the float, Actinium Pharmaceuticals, Inc. (NYSE: ATNM) has a structure that has historically been associated with higher potential for growth as interest builds. 4. Upcoming Clinical Data: Key proof-of-concept clinical data is expected to be released in late 2025, with trials assessing targeted radiotherapy in combination with PD-1 inhibitors like KEYTRUDA® and OPDIVO®—a development that could be pivotal for Actinium Pharmaceuticals, Inc. (NYSE: ATNM). 5. Innovative Radiotherapy Approach: A mutation-agnostic targeted radiotherapy utilizing Actinium-225 is being developed to deliver radiation directly to cancer cells while minimizing damage to surrounding healthy tissue—an approach that Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is working to advance. 6. High-Profile Collaborations: A Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) underscores strong institutional backing for ongoing research—an initiative that Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is actively involved in. 7. Intellectual Property Strength: Intellectual Property Strength: With hundreds of patents, including exclusive rights to Actinium-225 production, Actinium Pharmaceuticals, Inc. (NYSE: ATNM) has built a strong foundation in next-generation radiotherapy. Consider Adding Actinium Pharmaceuticals, Inc. (NYSE: ATNM) To Your Radar This Morning… Not every biotech name earns a spot at the top of our watchlist—but Actinium Pharmaceuticals, Inc. (NYSE: ATNM) has been making moves that demand attention this morning. With the potential for bullish momentum unfolding, an approximate 26% move in recent sessions, and multiple Wall Street analysts setting aggressive targets, Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is one under the radar company to keep an eye on. Its upcoming clinical data, high-profile collaborations, and strong patent portfolio only add to the case.  When a company with this kind of structure starts gaining momentum, it’s worth paying attention. That’s why we have all eyes on (ATNM) this morning.  (ATNM) moved approximately 15% in the early session from $1.19 to $1.38, lighting up Multiple Bullish Signals on TradingView’s technical analysis tool while breaking past several key moving averages.  Please keep an eye out for my next update—could be at any moment. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and StockNewsTrends is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of TD Media LLC owns and operates stocknewstrends . com (“SNT”). From time to time, SNT will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: stocknewstrends.com/disclosure/  *Pursuant to an agreement between TD Media LLC and Sica Media LLC, TD Media LLC has been hired for a period beginning on 03/20/2025 and ending on 03/20/2025 to publicly disseminate information about (ATNM:US) via digital communications. Under this agreement, TD Media LLC has been paid twenty thousand USD (“Funds”). To date, including under the previously described agreement, TD Media LLC has been paid one million eight thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither TD Media LLC and their member own shares of (ATNM:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/atnm/#details

TD Media LLC | 5826 New Territory Blvd. Unit #2144 | Sugar Land, TX 77479 US Unsubscribe | Update Profile | Constant Contact Data Notice